The-LDN-Book-3

The LDN Book 3: Low Dose Naltrexone: The Latest Research on: Viral Infections, Long COVID, Mold Toxicity, Longevity, Cancer, Depression and More.

Written by Medical Professionals, learn how Low Dose Naltrexone (LDN) can help with COVID and prolonged COVID, viruses, mold, CIRS, disease, cancer and more.

The LDN Book 3 followis on from the success of Books 1 & 2, includes:

Pharmacology and Best Clinical Practices, Drug-Resistant Depression, Virally Damaged Tissues (including COVID-19, Herpes Simplex (HSV 1 & 2), Varicella-Zoster, Human Parvovirus B19 (B19V), Epstein-Barr (EBV), LDN and Longevity, Mixed Connective Tissue Disease (MCTD), Mold Illness and CIRS, Ophthalmic Conditions, Long COVID, Cancer, and Case Studies, Dosing Protocols with pages of references!

Authors include Pharmacist Stephen Dickson, Dr. Elizabeth Livengood. Dr. Sarah Zielsdorf. Dr. Yusuf M. (JP) Saleeby, Dr. Deanna Windham, Dr. Kent Holtorf, Pharmacist Sebastian Denison. Professor Angus Dalgleish, Dr. Wai Liu, and Dr. Nasha Winters

Autoimmune Diseases, Cancers, Chronic Pain, etc have high levels of inflammation.

Best Seller Author Dr. Pamela W. Smith, MD, MPH, MS said "The great news is that inflammation can be balanced using many modalities from traditional medications to changing eating habits, to adding nutrients and herbal therapies, along with the newest treatment, Low Dose Naltrexone. LDN is a prescription compounded medication that very effectively reduces inflammation.

Low Dose Naltrexone has been shown to be one of the keys to the future of medicine for many disease processes that are inflammatory in nature. It is also an efficacious pain control agent.

It is my hope, and the hope of the world-class authors of this book, that you begin your medical journey toward healing by learning more about this wonderful medication"

Purchase Now

Place Bulk Orders

Who Wrote What in the Book?

Preface by Linda Elsegood, Founder LDN Research Trust
Foreword by Pamela W. Smith, M.D., MPH, MS
Pharmacology and Best Clinical Practices by J. Stephen Dickson, BSC (hons) MRPharmS

I'm Stephen Dickson. I am a pharmacist and I've been working with the LDN Research Trust for over a decade and dispensing LDN to tens of thousands of patients in the EU and the UK. I have the honor of writing the first chapter of the Third LDN Book, Chapter One Pharmacology and Best Clinical Practices. Now this chapter will give you an overview of the pharmacology that is how the drug works, which receptors it works on and what that actually means for the body and how it improves health in certain conditions and also how clinicians should best use it in their patient group.

Drug-Resistant Depression by Dr. Elizabeth Livengood, NMD

Hi I'm Dr Elizabeth Livengood and I've written a chapter for the LDN Research Trust called Drug Resistant Depression. Whether you are a health care provider or a loved one of someone experiencing chronic depression I know you will find some fascinating new research about the different causes of depression and why conventional medications don't always work. Did you know only 28 percent of patients respond to monotherapy for antidepressant medications? That means almost three-fourths of patients don't respond. The clues as to why people do not respond to medications lie in a thorough family history, a personal health history and specific medical tests. We'll review how you can run a few of these tests and predict if a person will actually respond to an SSRI. You'll be prepped with questions to ask your doctor if you're a patient or if you're a doctor questions that you really need to ask your patients. We'll explore trauma, insomnia, lifestyle, habits, dysbiosis, menopause and so much more. Join me in learning more in the LDN Book Number Three.

Virally Damaged Tissues ( including: COVID-19, Herpes Simplex (HSV 1 & 2), Varicella-Zoster, Human Parvovirus B19 (B19V), Epstein-Barr (EBV)by Sarah J. Zielsdorf, MD, MS

I'm Dr. Sarah Zielsdorf, an internist, microbiologist, medical advisor and the education director for the LDN Research Trust. I'm an author in the LDN Book 3 for Chapter 3, Treating Virally Damaged Tissues with LDN. Profound cellular injury occurs due to a severe case of COVID-19 as the central component we have DNA damage that can occur, viral illnesses lead to viral toxemia. COVID-19 often causes reactivation of dormant viruses including herpes simplex virus 1 and 2. Epstein-Barr virus, Varicella Zoster and parvovirus b19. Injury to gut and pulmonary tissues lead to polymer microbial sepsis. Hyperactivation of toll-like receptors leads to cytokine storm. Attenuating toll-like receptor 4 is central for treating COVID the targets are the gut and lung tissues. LDN is the most well-studied and well-established attenuator of multiple toll-like receptors.

LDN and Longevity by Yusuf M. (JP) Saleeby, MD

Hi my name is Yusuf Saleeby, otherwise known as JP Saleeby. I am a functional medicine physician and a director of the Carolina Holistic medicine centers in South Carolina, as well as, our non-profit Priority Health Academy which is a teaching Institution for functional medicine practitioners. I have the privilege of serving on the LDN Research Trust medical Advisory Board. Linda Elsegood had tasked me with writing a chapter on longevity. This is a very broad topic. I am discussing LDN as a standalone therapy or in conjunction with other agents for increasing longevity and health span. This can impact such conditions as autoimmune disease, immune dysregulation, mood disorder and cancer amongst others.

Mixed Connective Tissue Disease by Deanna Windham, DO

I am Dr Deanna Windham and thank you for joining me in the chapter called An Integrative Approach to Mixed Connective Tissue Disease. This is a complicated disease process that is difficult to make the diagnosis for clinicians and difficult to live with for patients, but in this chapter we're going to talk about how to nail the diagnosis every time so that you never miss it again. We're also going to talk about some exciting new treatment options and what we can do to help people with mixed connective tissue disease to live vibrant and healthy lives. We're also going to highlight LDN or Low Dose Naltrexone and how it works specific to mixed connective tissue disease and some of my experience with it. I'm excited to have you join us in the chapter and I hope that you get a lot out of it.

Mold Illness and CIRS by Kent Holtorf, MD

I'm Dr Kent Holtorf with the Holtorf Medical Group and founder of Integrative Peptides and chief science officer of KJ Biofarm. I wrote chapter six, LDN and Mold Illness and the Updated Peptide Protocol for the Rapid Treatment of CIRs or Chronic Inflammatory Response Syndrome. The chapter builds on the current standard protocol and demonstrates that the focus on immune modulators such as LDN and peptides can dramatically and much more quickly get these patients better because as explained in the chapter CIRs is fundamentally an illness of the immune system that results in a vicious cycle of the the multi-system illness that it is. Well the current protocol for mold illness and subsequent CIRs indirectly treats the abnormal immunity it's actually the last thing to be significantly addressed. So this is what needs to be done initially making it much easier for every other physiologic abnormality and associated symptom to be able to normalize. It makes it much easier to get better and with all these multi-system physiological abnormalities. So this chapter will basically demonstrate how to get better faster and easier. If you miss the immune dysfunction you're likely in for a long protracted treatment and it allows you to limit your suffering or for those of your loved ones and allow you to able to return to normal functioning much quicker.

Ophthalmic Conditions by Sebastian Denison, RPh, FAAR

My name is Sebastian Denison. The chapter that I contributed to looked at the use of LDN in the eye for both providers and patients and its use in helping control inflammation and helping with post-surgical and trauma healing. This is an exciting chapter because we're looking at the evidence over the last 15 years and how it contributes to the utilization in a safe and potentially effective manner.

Long COVID by Professor Angus G. Dalgleish, FRCP FRCPath FMedSci and Wai M. Liu, PhD

I'm Angus Dalgleish, Professor of Oncology at St George's University of London and Principal of The Institute of Cancer Vaccines and Immunotherapy and I have written a chapter eight on the effects of long Low Dose Naltrexone and long COVID. I also have written the next chapter which is on the use of long a Low Dose Naltrexone and cancer and these are actually quite linked as we found one of the mechanisms that LDN operates through that it probably explains why it is so effective in cancer is shared with patients who develop long COVID and that is the inflammatory pathway that leads to the production of interleukin-6 which is the hallmark of cancers that progress but is also a hallmark of acute and long COVID. In this chapter we discussed the possible mechanisms but even more importantly the fact that giving patients a Low Dose Naltrexone who've suffered long long COVID for over a year has led to dramatic improvements in their symptoms. Sometimes it really is dramatic in two or three weeks, other times it takes slightly longer and we know that the link is real because if you withdraw the Low Dose Naltrexone too early they relapse. Reintroduce it and they benefit again. So I think you will find the use of the Low Dose Naltrexone in long COVID patients and their remarkable recoveries really most interesting and I am surprised it has not become a standard of care. And I have written chapter nine about the role of Low Dose Naltrexone in cancer patients. I did not read or learn of LDN and cancer from any other source than asking patients who were doing remarkably well if they were taking anything else. It was this was how I learned that some cancers seem to stabilize with Low Dose and Naltrexone and in this chapter I not only go through the mechanisms we now know that there are at least three major scientific pathways that Naltrexone inhibits that are related to cancer but also several remarkable anecdotes which I'm sure you will find of great interest. And I have an absolute privilege and honor to join other incredible influential colleagues and mentors of mine in sharing wisdom of how Low Dose Naltrexone has impacted our lives both personally and professionally and I'm part of a chapter where I get to splash around and sharing with you some of the really amazing cases that blew away in my approach to cancer care and so I hope that you have some curiosity to dig deeper into some cases of where Low Dose Naltrexone made all the difference in patients dealing with cancer.

Cancer and Case Studies by Angus Dalgleish,FRCP FRCPath FMedSc Wai M. Liu, PhD and Nasha Winters, ND, FABNO
Epilogue by Yoon Hang “John” Kim, MD
APPENDIX- Dosing Protocols by Sarah J. Zielsdorf, MD, MS

The Authors talk about their Chapters: https://www.youtube.com/embed/-a2kNYakWZ4

Review and Praise for The LDN Book 3

“Building on the valuable information shared in the first two volumes of The LDN Book, book three is an equally important and authoritative treasure trove of documented research furthering our understanding of naltrexone. Essential reading for clinicians and patients alike!” by Larry Trivieri, Jr. Author and Health Freedom Advocate

“Praises to Linda Elsegood through the LDN Research Trust for once again compiling such a comprehensive, informative book on LDN and its multitude of uses, filled with so many practical and relevant usages of LDN! I would highly recommend it to all who are interested in the potential of LDN's efficacy in today's integrative world. This book contains current clinical research, up-to-date protocols, and appropriate dosing for LDN. I cannot speak more highly of such a pertinent book regarding LDN!” by Lisa Hunt, DO, DOH, Specializing in strengthening the immune system, anti-aging, etc

“The LDN Book 3 Is an invaluable resource for all clinicians that treat patients suffering from chronic inflammatory conditions. The book offers detailed references, protocols, insight, and information on how to use low dose naltrexone to treat CIRS, latent viral infections, autoimmune conditions, refractive depression, and many other challenging conditions. Like the previous two books, Book 3 is a must-have for any physician.” by Alina D Garcia MD, Specializing in fibromyalgia, chronic fatigue, Lyme and CIRS, etc

“This book is gold! It is a science-based, effective solution to the rampant chronic health problems that plague millions today. It is easy to understand, simple to implement, and most importantly, will be a guiding light for so many who are out of answers and are desperately searching for a path home to health.” Dr. Mindy Pelz, DC, Bestselling author of The Reset Factor, The Reset Factor Kitchen, and The Menopause Reset

“Rarely does a naturopathic doctor consider any medicine to be a “miracle drug,” but LDN has been a life-altering medicine for my patients. Kudos to Linda Elsegood for once again offering a resource for patients worldwide.” by Dr. Nancy L. Evans, ND, Specializing in HRT and thyroid disorders

“A wonderful resource to build upon patients’ and clinicians’ knowledge of LDN by adressing current research and new applications of the medication.” by Dr. Jennifer Rickner, PharmD, RP, Compounding Pharmacist and LDN Specialist

“The LDN Books continue to be a treasure chest of information. We recommend them to our patients and practitioners. Book 3 I carries on this tradition of being a timely and valuable resource on the many conditions that benefit from LDN.” by Steve Hoffart, PharmD, Compounding Pharmacist

“The LDN Book 3 gives valuable insight into the drug of the decade. The immense knowledge within can change and improve the quality of life. For many, it’s a game changer.” by Nat Jones, R.Ph. FAPC, Clinical Compounding Pharmacist

The LDN Book 3 Supporters

Click H ERE to find an LDN Book Stockists